OpenDNA and Harper Health have announced a clinical partnership to provide AI-based genetic risk testing to patients across the U.S. The collaboration will integrate OpenDNA’s advanced polygenic risk score (PRS) technology into Harper Health’s personalized concierge care model.
This collaboration will provide Harper Health patients with valuable insights into their risk for cardiovascular disease, cancer, and other health conditions through OpenDNA’s CardioRisk+, CancerRisk+, and TotalRisk+ tests.
“At Harper Health, we are committed to providing our patients with the most advanced and personalized healthcare available,” said Dr. William Harper, MD FACP, Founder and CEO at Harper Health. “By partnering with OpenDNA, we can now offer genetic screening that empowers our patients to take proactive steps towards managing their health and preventing future illness. Understanding individual risk profiles enables our physicians to provide more targeted and effective preventive care recommendations. We are excited to integrate the innovative OpenDNA tests and platform into our clinical protocols now, as we believe that genetic screening tests should become the standard of care.”
“We are thrilled to partner with Harper Health to bring our innovative genetic AI solutions to their patients,” said Dr. Eran Feldhay, Founder and CEO at OpenDNA. “We believe that everyone should have access to information about their genetic predispositions, and we are confident that this partnership will significantly impact the health and well-being of Harper Health patients. Our products provide actionable insights that can empower individuals to take control of their health.”
OpenDNA continues to expand its network of physician-led collaborations with a focus on embedding genomic insights directly into everyday care. With Harper Health’s commitment to longevity-focused, patient-first medicine, this partnership exemplifies how technology and clinical relationships can align to improve long-term health outcomes.
